Evidence map›Paper›PMID 39617422›Full record

ArticleBrain pathology (Zurich, Switzerland)2025

Neuropathological and cerebrospinal fluid correlates of choroid plexus inflammation in progressive multiple sclerosis.

R Magliozzi, S Hametner, M Mastantuono, A Mensi, M Karimian, L Griffiths, L M Watkins, A Poli, G M Berti, E Barusolo and 10 more

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

R MagliozziNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.ORCID 0000-0001-8284-7763
S HametnerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
M MastantuonoNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
A MensiNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
M KarimianNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
L GriffithsInstitute of Life Sciences, Swansea University, Swansea, UK.ORCID 0000-0002-8713-3687
L M WatkinsInstitute of Life Sciences, Swansea University, Swansea, UK.
A PoliNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
G M BertiNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
E BarusoloNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
B BelliniNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
S RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
D GvericDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
J A StrattonDepartment of Neurology and Neurosurgery, McGill University, Montreal, Canada.
K AkassoglouGladstone Institute of Neurological Disease, San Francisco, California, USA.
S MagonRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
R NicholasDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
R ReynoldsDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
O W HowellInstitute of Life Sciences, Swansea University, Swansea, UK.ORCID 0000-0003-2157-9157
S MonacoNeurology Section of Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Funding

Italian MS Foundation FISM 2023/R-Single/038MS Society of Great Britain 007/14MUR Excellence Project 2023-2027the BRAIN Unit Infrastructure Awardthe National Recovery and Resilience Plan (NRRP) MNESYS (PE0000006)the Research Wales Innovation FundWelsh Government through Health and Care Research Wales UA05
6 · The paper itself

Abstract

Among the intrathecal inflammatory niches where compartmentalized inflammation persists and plays a pivotal role in progressive multiple sclerosis (MS), choroid plexus (CP) has recently received renewed attention. To better characterize the neuropathological/molecular correlates of CP in progressive MS and its potential link with other brain inflammatory compartments, such as perivascular spaces and leptomeninges, the levels, composition and phenotype of CP immune infiltration in lateral ventricles of the hippocampus were examined in 40 post-mortem pathologically confirmed MS and 10 healthy donors, using immunochemistry/immunofluorescence and in-situ sequencing. Significant inflammation was detected in the CP of 21 out of the 40 MS cases (52%). The degree of CP inflammation was found correlated with: number of CP macrophages (R: 0.878, p = 1.012 x 10

Indexed as

Choroid PlexusInflammationMultiple Sclerosis, Chronic ProgressiveAdultAgedFemaleHumansMacrophagesMaleMiddle AgedMultiple Sclerosischoroid plexusgradientinflammationmultiple sclerosis

Identifiers

PMID39617422
PMCPMC12145902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.